ArticleScientific reports2021
Surface plasmon resonance unveils important pitfalls of enzyme-linked immunoassay for the detection of anti-infliximab antibodies in patients' sera.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Improved VSV-Ebola-GP booster vaccination approach promotes antibody affinity maturation and durable anti-Ebola immunity in humans.Nature immunology · 2026Trial
- Development of a portable device for the detection of anti-PEG antibodies in human plasma.Scientific reports · 2026Article
- An LSPR-Based Kinetic Framework for Polyelectrolyte Molecular Weight Determination: A Proof-of-Concept Study.Analytical chemistry · 2026Article
- Article
- Drug-Tolerant, Chemiluminescent Lateral Flow Immunoassay Platform for the Determination of Neutralizing Anti-Drug Antibodies.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Article
- A deeper evaluation of cytokeratin fragment 21-1 as a lung cancer tumor marker and comparison of different assays.Biosensors & bioelectronics: X · 2025Article
- Detection of antibodies to infliximab in routine care: a 4-year French retrospective study.Clinical and experimental immunology · 2025Article
- Isolation of a nanobody specific to the PstS-1 protein and evaluation of its immunoreactivity with structural components ofFrontiers in immunology · 2025Article
- The first WHO reference panel for Infliximab anti-drug antibodies: a step towards harmonizing therapeutic drug monitoring.Frontiers in immunology · 2025Article
- Review
- Evaluating the Performance of Two Automated Anti-drug Antibodies Assays for Infliximab and Adalimumab Without Acid Dissociation.The AAPS journal · 2024Article
- Artificial Intelligence-Powered Molecular Docking and Steered Molecular Dynamics for Accurate scFv Selection of Anti-CD30 Chimeric Antigen Receptors.International journal of molecular sciences · 2024Article
- Development of a Bispecific IgG1 Antibody Targeting BCMA and PDL1.Antibodies (Basel, Switzerland) · 2024Article
- Kinetic study of membrane protein interactions: from three to two dimensions.Scientific reports · 2024Article
- Approaches for the detection and analysis of antidrug antibodies to biopharmaceuticals: A review.Journal of separation science · 2022Review
- Switching Among Biosimilars: A Review of Clinical Evidence.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Measurements of serum concentrations of therapeutic antibodies and anti-drug antibodies (ADA) can support clinical decisions for the management of non-responders, optimizing the therapy. In the present study we compared the results obtained by classical ELISA and a recently proposed surface plasmon resonance (SPR)-based immunoassay, in 76 patients receiving infliximab for inflammatory bowel diseases. The two methods indicated very similar serum concentrations of the drug, but there were striking differences as regards ADA. All the sera showing ADA by ELISA (14) also showed ADA by SPR, but the absolute amounts were different, being 7-490 times higher with SPR, with no correlation. Eight patients showed ADA only with SPR, and these ADA had significantly faster dissociation rate constants than those detectable by both SPR and ELISA. The underestimation, or the lack of detection, of ADA by ELISA is likely to reflect the long incubation steps which favor dissociation of the patient's low-affinity ADA, while the commercial, high-affinity anti-infliximab antibodies used for the calibration curve do not dissociate. This problem is less important with SPR, which monitors binding in real time. The possibility offered by SPR to detect ADA in patients otherwise considered ADA-negative by ELISA could have important implications for clinicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.